Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
Age Factors
Aged
Antiemetics
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ adverse effects
Female
Humans
Incidence
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Multicenter Studies as Topic
Nausea
/ chemically induced
Observational Studies as Topic
Paclitaxel
/ adverse effects
Pemetrexed
/ adverse effects
Propensity Score
Prospective Studies
Risk Assessment
/ statistics & numerical data
Risk Factors
Sex Factors
Vomiting
/ chemically induced
Antiemetics
Carboplatin
Chemotherapy-induced nausea and vomiting
Classification
Emetogenicity
Lung cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Jan 2021
15 Jan 2021
Historique:
received:
28
05
2020
accepted:
11
01
2021
entrez:
16
1
2021
pubmed:
17
1
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy. Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy. Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, P = 0.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, P = 0.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting. The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compare the incidence of CINV between lung cancer patients undergoing carboplatin plus pemetrexed (CBDCA+PEM) and those undergoing carboplatin plus paclitaxel (CBDCA+PTX) chemotherapy.
METHODS
METHODS
Pooled data of 240 patients from two prospective observational studies were compared using propensity score matching. Separate multivariate logistic regression analyses were used to identify risk factors for nausea and vomiting following chemotherapy.
RESULTS
RESULTS
Delayed nausea was significantly more common in patients treated with CBDCA+PEM than in those treated with CBDCA+PTX (51.1% vs. 36.2%, P = 0.04), but the incidence of vomiting did not significantly differ between the two groups (23.4% vs. 14.9%, P = 0.14). The occurrence of CINV peaked on day 4 in the CBDCA+PTX group and on day 5 in the CBDCA+PEM group. Multivariate analysis showed that female sex, younger age, and CBDCA+PEM regimen were independent risk factors for delayed nausea, while female sex was an independent risk factor for delayed vomiting.
CONCLUSIONS
CONCLUSIONS
The CBDCA + PEM regimen has a higher risk of causing delayed nausea than the CBDCA + PTX regimen, and aggressive antiemetic prophylaxis should be offered to patients treated with CBDCA + PEM.
Identifiants
pubmed: 33451299
doi: 10.1186/s12885-021-07802-y
pii: 10.1186/s12885-021-07802-y
pmc: PMC7811213
doi:
Substances chimiques
Antiemetics
0
Pemetrexed
04Q9AIZ7NO
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Références
Lancet Oncol. 2020 Feb;21(2):242-249
pubmed: 31838011
Support Care Cancer. 2010 Sep;18(9):1171-7
pubmed: 19756774
Support Care Cancer. 2011 Jun;19(6):807-13
pubmed: 20461438
BMC Pharmacol Toxicol. 2020 Oct 6;21(1):72
pubmed: 33023657
Cancer Chemother Pharmacol. 2018 Jan;81(1):103-109
pubmed: 29124327
Support Care Cancer. 2017 Jan;25(1):289-294
pubmed: 27510316
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
Support Care Cancer. 2017 Jan;25(1):271-275
pubmed: 27501965
Anticancer Res. 2015 Aug;35(8):4527-34
pubmed: 26168497
Support Care Cancer. 2012 Jan;20(1):107-17
pubmed: 21258948
Lung Cancer. 2015 Dec;90(3):410-6
pubmed: 26791800
N Engl J Med. 2016 Jul 14;375(2):134-42
pubmed: 27410922
Lung Cancer. 2014 Jun;84(3):259-64
pubmed: 24746177
Ann Oncol. 2012 Aug;23(8):1986-1992
pubmed: 22396444
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Support Care Cancer. 2017 Sep;25(9):2707-2714
pubmed: 28341971
Support Care Cancer. 2018 Nov;26(11):3773-3780
pubmed: 29808377
Cancer. 2016 Aug 1;122(15):2418-25
pubmed: 27176138
Cancer Chemother Pharmacol. 2019 Jul;84(1):147-153
pubmed: 31087137
Int J Clin Oncol. 2015 Oct;20(5):855-65
pubmed: 25681876
Br J Cancer. 2013 Aug 20;109(4):859-65
pubmed: 23860530
Int J Clin Oncol. 2016 Jun;21(3):491-7
pubmed: 26662632